Skip to content
TrialScanner

NCT04853017

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Phase 1CompletedELTXLead

Registry record

Lead sponsor
Elicio Therapeutics
Conditions
Minimal Residual Disease; KRAS G12D; KRAS G12R; NRAS G12D; NRAS G12R
Primary completion
Jan 26, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04853017 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04853017: A Study of ELI-002 in... | TrialScanner